Maravai LifeSciences Holdings, Inc. (MRVI)
| Market Cap | 1.30B +127.1% |
| Revenue (ttm) | 204.73M -15.4% |
| Net Income | -104.56M |
| EPS | -0.72 |
| Shares Out | 258.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,807,795 |
| Open | 5.10 |
| Previous Close | 5.02 |
| Day's Range | 4.99 - 5.19 |
| 52-Week Range | 1.99 - 5.21 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 5.70 (+13.1%) |
| Earnings Date | May 7, 2026 |
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents ... [Read more]
Financial Performance
In 2025, MRVI's revenue was $185.74 million, a decrease of -28.34% compared to the previous year's $259.19 million. Losses were -$130.77 million, -9.72% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MRVI stock is "Buy." The 12-month stock price target is $5.7, which is an increase of 13.10% from the latest price.
News
Maravai LifeSciences Holdings Transcript: Jefferies Global Healthcare Conference 2026
Significant cost reductions and operational streamlining have driven improved margins and cash flow. Commercial execution, product innovation (notably ModTail), and e-commerce expansion are fueling growth, with further upside expected from new product launches and geographic expansion, especially in China.
Maravai Lifesciences announces refinancing of credit agreement
Maravai LifeSciences (MRVI) Holdings announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150M term loan facility and a $30M revolving…
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that cert...
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company w...
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Maravai Lifesciences (MRVI) to $6 from $4.50 and keeps a Buy rating on the shares.
Maravai LifeSciences Holdings Slides: Investor presentation
Maravai LifeSciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Maravai LifeSciences Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 41% revenue growth year-over-year, strong TriLink and Cygnus performance, and positive free cash flow. Full-year guidance was raised for both revenue and EBITDA, driven by high-margin GMP consumables and operational improvements.
Maravai LifeSciences Holdings Earnings release: Q1 2026
Maravai LifeSciences Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Maravai LifeSciences Holdings Slides: Q1 2026
Maravai LifeSciences Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Maravai LifeSciences Holdings Quarterly report: Q1 2026
Maravai LifeSciences Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
Maravai LifeSciences Holdings Proxy statement: Proxy filing
Maravai LifeSciences Holdings filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Maravai LifeSciences Holdings Proxy statement: Proxy filing
Maravai LifeSciences Holdings filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fi...
Maravai LifeSciences Holdings Slides: Investor presentation
Maravai LifeSciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Maravai Lifesciences price target raised to $3 from $2 at Baird
Baird raised the firm’s price target on Maravai Lifesciences (MRVI) to $3 from $2 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results…
Maravai LifeSciences Holdings Earnings Call Transcript: Q4 2025
Delivered revenue and adjusted EBITDA above expectations, driven by cost savings, new product launches, and strong customer demand. Guidance for 2026 calls for 8–13% revenue growth, margin expansion, and continued operational improvements.
Maravai LifeSciences Holdings Annual report: Q4 2025
Maravai LifeSciences Holdings has published its Q4 2025 annual report on February 25, 2026.
Maravai LifeSciences Holdings Earnings release: Q4 2025
Maravai LifeSciences Holdings released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Maravai LifeSciences Holdings Slides: Q4 2025
Maravai LifeSciences Holdings has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Maravai LifeSciences Holdings Annual report: Q4 2025
Maravai LifeSciences Holdings has published its Q4 2025 annual report on February 25, 2026.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fo...
Maravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo
Wells Fargo analyst Brandon Couillard raised the firm’s price target on Maravai Lifesciences (MRVI) to $4.50 from $4 and keeps an Overweight rating on the shares. With U.S. policy uncertainty…
Maravai LifeSciences Holdings Transcript: Jefferies London Healthcare Conference 2025
Management executed major cost reductions and centralized operations, setting up for scalable growth and profitability. Focused on high-impact products and larger customer orders, the business expects improved visibility, new product traction, and international expansion to drive growth through 2026.